NCT02326727

Brief Summary

Regional anesthesia may decrease the release of endogenous opioids, increase Natural Killer cell (NK) function and decrease development of metastasis. The recent analysis of the Cancer Registry has noted an improved 5-year survival in patients who received epidural analgesia during surgery for colorectal carcinoma.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2015

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 10, 2014

Completed
19 days until next milestone

First Posted

Study publicly available on registry

December 29, 2014

Completed
3 months until next milestone

Study Start

First participant enrolled

April 1, 2015

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2017

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2017

Completed
Last Updated

December 29, 2014

Status Verified

December 1, 2014

Enrollment Period

2 years

First QC Date

December 10, 2014

Last Update Submit

December 22, 2014

Conditions

Keywords

Epidural AnalgesiaNatural Killer Cells

Outcome Measures

Primary Outcomes (2)

  • Count of live and dead target erythroleukemic cells

    All clinical and laboratory parameters from blood samples taken before and after the operation will be compared between the two groups of patients. The nominal data comparison will be performed by ANOVA test, and the nonparametric data will be performed by Mann-Whitney test and interquartile ranges (IQR) for non-normally distributed data.

    72 hours

  • Plasma concentration of cytokines

    All clinical and laboratory parameters from blood samples taken before and after the operation will be compared between the two groups of patients. The nominal data comparison will be performed by ANOVA test, and the nonparametric data will be performed by Mann-Whitney test and interquartile ranges (IQR) for non-normally distributed data.

    72 hours

Study Arms (2)

General Anesthesia

ACTIVE COMPARATOR

Patients receiving general anesthesia with Fentanyl,Propofol, Isoflurane and Nitrous Oxide only during colonic cancer surgery

Drug: FentanylDrug: PropofolDrug: IsofluraneDrug: Nitrous Oxide

Combined anesthesia

ACTIVE COMPARATOR

Patients receiving general anesthesia and epidural analgesia with Ropivacaine during colonic cancer surgery

Drug: RopivacaineDrug: FentanylDrug: PropofolDrug: IsofluraneDrug: Nitrous Oxide

Interventions

Epidural analgesia

Combined anesthesia

General Anesthesia

Combined anesthesiaGeneral Anesthesia

General Anesthesia

Combined anesthesiaGeneral Anesthesia

General Anesthesia

Combined anesthesiaGeneral Anesthesia

General Anesthesia

Combined anesthesiaGeneral Anesthesia

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patients undergoing colonic cancer surgery

You may not qualify if:

  • Patients with poor physical status Patients needed emergency surgery Coagulopathic disorders with international normalized ratio (INR) level more than 1.4 Thrombocytopenia with platelets count less 100000 per mcl Allergic reaction to local anesthetics in patient history Failure to performing the epidural analgesia from another cause Preoperative immunomodulating treatment Recent history of chemotherapy or radiation therapy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hillel Yaffe Medical Center

Hadera, 38100, Israel

Location

MeSH Terms

Conditions

Colonic Neoplasms

Interventions

RopivacaineFentanylPropofolIsofluraneNitrous Oxide

Condition Hierarchy (Ancestors)

Colorectal NeoplasmsIntestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal Diseases

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsMethyl EthersEthersNitrogen OxidesGasesInorganic ChemicalsNitrogen CompoundsOxidesOxygen Compounds

Central Study Contacts

Leonid Reytman, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 10, 2014

First Posted

December 29, 2014

Study Start

April 1, 2015

Primary Completion

April 1, 2017

Study Completion

May 1, 2017

Last Updated

December 29, 2014

Record last verified: 2014-12

Locations